By Kathleen Gallagher of the Journal Sentinel
Nov. 16, 2010
Stratatech Corp. said Tuesday it has received a $3.5 million federal innovation grant to expand development of its anti-infective living human skin substitute.
The privately held Madison company received the fast-track Small Business Innovation Research grant from the National Institute of Allergy and Infectious Diseases. Stratatech was one of just a few companies that received awards to develop therapies and diagnostic tools for drug-resistant bacteria with selected partners.
The company will partner with the Armed Forces Institute of Pathology, the University of Wisconsin-Madison and the Waisman Clinical Biomanufacturing Facility.